Search results

    Search results

    Show all results for ""
    Can not find any results or suggestions for "."

    Search tips

    • Make sure there are no spelling errors
    • Try different search terms or synonyms
    • Narrow your search for more hits

    How can we help?

    Contact Us

    Find Employees

    University of Skövde, link to startpage

    Search results

      Search results

      Show all results for ""
      Can not find any results or suggestions for "."

      Search tips

      • Make sure there are no spelling errors
      • Try different search terms or synonyms
      • Narrow your search for more hits

      How can we help?

      Contact Us

      Find Employees

      University of Skövde, link to startpage

      CardioTrophy - for reduced morbidity and mortality in cardiovascular diseases

      Research Group Translational Bioinformatics
      Resarch Environment Systems Biology

      CardioTrophy - for reduced morbidity and mortality in cardiovascular diseases

      Research Group Translational Bioinformatics
      Resarch Environment Systems Biology

      Quick Facts

      Full project name

      Human stem cell based in vitro model for studies of cardiac hypertrophy

      Duration

      March 2017 – February 2021

      Funding and collaboration

      The Knowledge Foundation, Astra Zeneca, Takara Bio Europe AB

      The advancement in stem cell research over the last decade has now made it possible to generate large quantities of human specialized cells for in vitro applications. Specifically, in the drug discovery and development process this has important implications. The project involves studies of the genetic and molecular basis of hypertrophy and aims to develop new knowledge that can contribute to the development of novel therapies and treatments that can reduce cardiovascular morbidity and mortality.

      The generation of human cardiomyocytes from pluripotent stem cells allows the establishment of clinically relevant in vitro systems to test unwanted side-effects of novel drug candidates.

      Increased availability of human cardiomyocytes

      Previously, the access to human cardiomyocytes has been limited, and pharmaceutical industries have had to rely on non-human models for pre-clinical testing. These models have limited human relevance, which contribute to costly late stage attrition in drug development projects.

      This project addresses the need for new more advanced in vitro models to test adverse responses in human cardiomyocytes with a specific focus on cardiac hypertrophy.

      CardioTrophy wants to develop new knowledge

      The project involves studies of the genetic and molecular basis of hypertrophy and aims to develop new knowledge that can contribute to the development of novel therapies and treatments that can reduce cardiovascular morbidity and mortality. To this end, we are generating cardiomyocytes from human pluripotent stem cells for use in assay development.

      Induces a disease-like condition

      By exposing these cardiomyocytes to substances that are known to induce cardiac hypertrophy e.g. Endothelin-1 we are inducing a disease phenotype in vitro that mimic cardiac hypertrophy in vivo. This model is used to characterize the hypertrophic response on a mechanistic level using large-scale omics technologies such as transcriptomics and proteomics.

      Uses omics techniques

      These technologies generate large amounts of data, which is used to identify critical biomarkers that may constitute novel targets to assess cardiac hypertrophy. Our optimal goal is then to use this experimental system in combination with the biomarker(s) identified to develop, optimize, and implement a complete assay for human cardiac hypertrophy in a multi-well format that can be used in compound screens to assess if they induce any deleterious hypertrophic effects in the cells.

      Project Leader

      Professor of BioInformatics

      Participating Researchers

      Barbara Kuppers
      Takara Bio Europe AB

      Partners and financing

      Knowledge Foundation
      AstraZeneca
      Takara Bio Europe AB
      Published: 1/12/2021
      Edited: 1/12/2021
      Responsible: webmaster@his.se